logo-loader
viewSynairgen PLC

Synairgen’s LOXL2 fibrosis drugs ready for phase II trials

With the receipt of long-term toxicity results, Synairgen and Pharmaxis now have all the data they need to take to potential partners

liver
Synairgen has around a 17% carried financial interest in the twoLOXL2 inhibitors

Synairgen plc (LON:SNG) shares soared on Thursday after the respiratory drugs specialist confirmed its two Lysyl Oxidase Like 2 (LOXL2) inhibitors are now ready to enter phase II trials.

Pharmaxis, Synairgen’s partner in the programme, has received the results from three-month toxicology studies, completing the data package needed to advance talks with potential partners.

READ: Pharmaxis’ take on the latest progress

Aussie-listed Pharmaxis has been in talks with some “large pharma companies” over the past year or so and has now delivered the completed scientific package to those potential suitors.

“The successful completion of the longer-term toxicology studies completes the data set,” said Synairgen chief executive Richard Marsden.

“Pharmaxis is now conducting a final series of scientific briefings to potential partners. In accordance with the amended collaboration agreement with Pharmaxis, Synairgen will receive circa 17% of any future net partnering proceeds from all fibrotic indications for the LOXL2 inhibitors.

“We are really pleased about this positive development and look forward to further updates from Pharmaxis.”

Chances of ‘material upfront payment substantially increased’

Data from phase I trials back in November showed that the inhibitor compounds had the potential to be “best-in-class” treatments for a range of diseases such as Non‐alcoholic Steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF).

“These data complete the overall phase I data package enabling Pharmaxis to conduct a final series of scientific briefings with potential partners before licensing,” said finnCap analyst Mark Brewer in a note to clients.

“Given the significant interest in NASH from large pharma and the sizable licensing deals (both upfront and long-term ‘bio-dollars’) that have historically completed in this field, the probability of Synairgen receiving a material upfront payment has substantially increased.”

Synairgen shares surged 17.6% to 15.9p on Thursday.

Quick facts: Synairgen PLC

Price: 7.8 GBX

AIM:SNG
Market: AIM
Market Cap: £8.54 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Synairgen's phase II trial on lead COPD drug 'progressing well'

Synairgen PLC's (LON:SNG) Richard Marsden tells Proactive London's Andrew Scott  the respiratory drug discovery and development company, is well-poised to complete the phase II trial on its lead candidate. The trial is expected to complete dosing in Q1 next year with results available in...

on 30/9/19

2 min read